Eh, in many cases for actual customer-facing commercial work, they're sticking remarkably close to stuff that's in genbank/swissprot/etc - well characterized mo

Eh, in many cases for actual customer-facing commercial work, they're sticking remarkably close to stuff that's in genbank/swissprot/etc - well characterized molecules and pathways, because working with genuinely de novo stuff is difficult and expensive. In those cases, Alphafold works fine - it always requires someone to actually look at the results and see whether they make sense or not, but also "the part of the solution space where the tools work" is often a deciding factor in what approach is chosen.